Study part A ( @ healthy subjects ) was a single-dose , open-label , randomized , @-period crossover study to evaluate the BE of the dolutegravir/abacavir/lamivudine FDC tablet and dolutegravir + abacavir/lamivudine tablets in the fasted state .